This video highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
In this video, John O. Mascarenhas, MD, of the Tisch Cancer Institute at Mount Sinai in New York, highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
Mascarenhas presented results of the study (abstract 254) at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment
July 6th 2020The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.